MORAb 028
Alternative Names: MORAb-028; MT 228Latest Information Update: 23 Jan 2020
At a glance
- Originator Micromet Inc
- Developer Morphotek
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action GD2 ganglioside inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 16 Jul 2014 Discontinued - Phase-I for Malignant melanoma (Metastatic disease) in USA (Intratumoural & IV)
- 07 Jun 2011 Morphotek suspends a phase I trial for Malignant melanoma in USA (NCT01123304)
- 06 Oct 2010 Phase-I clinical trials in metastatic Malignant melanoma in USA (Intratumoural & IV)